drugset
drugset / Trial / NCT03588650

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

NCT03588650 ↗

Phase 1 Completed 26 enrolled Shanghai Henlius Biotech
NaSequentialOpen-labelTreatment

Summary

This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy.

Timeline

Start
2018-08-07
Primary completion
2021-06-28
Completion
2021-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject HLX20 Monoclonal antibody 1 mg/kg Other
Subject HLX20 Monoclonal antibody 3 mg/kg Other
Subject HLX20 Monoclonal antibody 10 mg/kg Other
Subject HLX20 Monoclonal antibody 20 mg/kg Other

Indications

cancer